{"disease":{"id":"metastatic-cancers","name":"metastatic cancers"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT04141397","title":"Real-world Clinical Effectiveness of Whole Genome and Transcriptome Analysis to Guide Advanced Cancer Care","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT05356741","title":"To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":645,"lead_sponsor_name":"Vir Biotechnology, Inc.","has_results":false},{"nct_id":"NCT06683846","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04907643","title":"Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT03386721","title":"Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":256,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06785636","title":"Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Pathos AI, Inc.","has_results":false},{"nct_id":"NCT06085716","title":"Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03942497","title":"Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America","phase":"","overall_status":"COMPLETED","enrollment_count":218,"lead_sponsor_name":"Latin American Cooperative Oncology Group","has_results":false},{"nct_id":"NCT02304809","title":"Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":216,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT06253520","title":"Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":210,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06929910","title":"Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Gene Solutions","has_results":false},{"nct_id":"NCT04799054","title":"A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":188,"lead_sponsor_name":"Ascendis Pharma Oncology Division A/S","has_results":false},{"nct_id":"NCT05639751","title":"PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT05838768","title":"Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":123,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06774027","title":"Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06678659","title":"A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Recursion Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT02408861","title":"Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03416244","title":"A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT06893380","title":"Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":61,"lead_sponsor_name":"CHA University","has_results":false},{"nct_id":"NCT02025192","title":"A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT03097601","title":"ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Centre Antoine Lacassagne","has_results":false},{"nct_id":"NCT05299125","title":"Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"Latin American Cooperative Oncology Group","has_results":false},{"nct_id":"NCT06549907","title":"A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT07071103","title":"Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Chuangzhen Chen","has_results":false},{"nct_id":"NCT07003022","title":"Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03388632","title":"Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07236021","title":"e-Motion : Promoting Emotion Regulation in Chronic Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Université Libre de Bruxelles","has_results":false},{"nct_id":"NCT02457793","title":"A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT04958434","title":"Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Suzhou Transcenta Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT06689540","title":"Mts105 for Advanced Hepatocellular Carcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":14,"lead_sponsor_name":"Shen Lin","has_results":false},{"nct_id":"NCT06194877","title":"A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"MapKure, LLC","has_results":false},{"nct_id":"NCT02376933","title":"Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer","phase":"NA","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"University of Arizona","has_results":true},{"nct_id":"NCT06682806","title":"A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT06690281","title":"A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03842865","title":"Expanded Access of Vigil in Solid Tumors","phase":"","overall_status":"TEMPORARILY_NOT_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Gradalis, Inc.","has_results":false}],"total":37},"guidelines":[],"source":"Drug Landscape verified database"}